Two clinical scenarios, namely SGLT2 inhibitors for heart failure and PD-1/PD-L1 inhibitors for advanced NSCLC were used to assess performance in evidence generation, evidence synthesis, and clinical judgment. Here, SLC5A2 is linked to non-small cell lung carcinoma.